|
1
|
Spizzo G, Went P, Dirnhofer S, Obrist P,
Moch H, Baeuerle PA, Mueller-Holzner E, Marth C, Gastl G and Zeimet
AG: Overexpression of epithelial cell adhesion molecule (Ep-CAM) is
an independent prognostic marker for reduced survival of patients
with epithelial ovarian cancer. Gynecol Oncol. 103:483–488. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Massoner P, Thomm T, Mack B, Untergasser
G, Martowicz A, Bobowski K, Klocker H, Gires O and Puhr M: EpCAM is
overexpressed in local and metastatic prostate cancer, suppressed
by chemotherapy and modulated by MET-associated miRNA-200c/205. Br
J Cancer. 111:955–964. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Köbel M, Kolloger SE, Boyd N, McKinney S,
Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, et al:
Ovarian carcinoma subtypes are different diseases: Implications for
biomarker studies. PLoS Med. 5:e2322008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fan Q, Cheng JC, Qui X, Chang HM and Leung
PC: EpCAM is up-regulated by EGF via ERK1/2 signaling and
suppresses human epithelial ovarian cancer cell migration. Biochem
Biophys Res Commun. 457:256–261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bignotti E, Tassi RA, Calza S, Ravaggi A,
Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S and Santin
AD: Differential gene expression profiles between tumor biopsies
and short-term primary cultures of ovarian serous carcinomas:
Identification of novel molecular biomarkers for early diagnosis
and therapy. Gynecol Oncol. 103:405–416. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
English DP, Bellone S, Schwab CL, Roque
DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S,
Ratner E, et al: Solitomab, an epithelial cell adhesion
molecule/CD3 bispecific antibody (BiTE), is highly active against
primary chemotherapy-resistant ovarian cancer cell lines in vitro
and fresh tumor cells ex vivo. Cancer. 121:403–412. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Osta WA, Chen Y, Mikhitarian K, Mitas M,
Salem M, Hannun YA, Cole DJ and Gillanders WE: EpCAM is
overexpressed in breast cancer and is a potential target for breast
cancer gene therapy. Cancer Res. 64:5818–5824. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thibault B, Castells M, Delord JP and
Couderc B: Ovarian cancer microenvironment: Implications for cancer
dissemination and chemoresistance acquisition. Cancer Metastasis
Rev. 33:17–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stronach EA, Cunnea P, Turner C, Guney T,
Aiyappa R, Jeyapalan S, de Sousa CH, Browne A, Magdy N, Studd JB,
et al: The role of interleukin-8 (IL-8) and IL-8 receptors in
platinum response in high grade serous ovarian carcinoma.
Oncotarget. 6:31593–31603. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Loose D and Van de Wiele C: The immune
system and cancer. Cancer Biother Radiopharm. 24:369–376. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kapka-Skrzypczak L, Popek S, Sawicki K,
Wolińska E, Czajka M and Skrzypczak M: Effect of IL-6 and IL-8 on
the expression of the complement activation inhibitors
MAC-inhibitory protein and decay-accelerating factor in ovarian
cancer A2780 cells. Oncol Lett. 12:1507–1512. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kulbe H, Chakravarty P, Leinster DA,
Charles KA, Kwong J, Thompson RG, Coward JI, Shioppa T, Robinson
SC, Gallagher WM, et al: A dynamic inflammatory cytokine network in
the human ovarian cancer microenvironment. Cancer Res. 72:66–75.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bonneau C, Rouzier R, Geyl C, Cortez A,
Castela M, Lis R, Daraï E and Touboul C: Predictive markers of
chemoresistance in advanced stages epithelial ovarian carcinoma.
Gynecol Oncol. 136:112–120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin J, Zeng F, Wu N, Kang K, Yang Z and
Yang H: Interleukin-8 promotes human ovarian cancer cell migration
by epithelial-mesenchymal transition induction in vitro. Clin
Transl Oncol. 17:365–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matysiak M, Kapka-Skrzypczak L,
Jodłowska-Jędrych B and Kruszewski M: EMT promoting transcription
factors as prognostic markers in human breast cancer. Arch Gynecol
Obstet. 295:817–825. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao
L, Yang H, Feng M, Xuan Y, Yang Y, et al: Tumor microenvironment:
The culprit for ovarian cancer metastasis? Cancer Lett.
377:174–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 26:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Bellone S, Siegel ER, Cocco E, Cargnelutti
M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S and
Santin AD: Overexpression of epithelial cell adhesion molecule in
primary, metastatic, and recurrent/chemotherapy-resistant
epithelial ovarian cancer: Implications for epithelial cell
adhesion molecule-specific immunotherapy. Int J Gynecol Cancer.
19:860–866. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Münz M, Kieu C, Mack B, Schmitt B, Zeidler
R and Gires O: The carcinoma-associated antigen EpCAM upregulates
c-myc and induces cell proliferation. Oncogene. 23:5748–5758. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Münz M, Zeidler R and Gires O: The
tumor-associated antigen EpCAM upregulates the fatty acid binding
protein E-FABP. Cancer Lett. 225:151–157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ni J, Cozzi P, Hao J, Beretov J, Chang L,
Duan W, Shigdar S, Delprado W, Graham P, Bucci J, et al: Epithelial
cell adhesion molecule (EpCAM) is associated with prostate cancer
metastasis and chemo/radioresistance via the PI3K/Akt/mTOR
signaling pathway. Int J Biochem Cell Biol. 45:2736–2748. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Farmer RW, Yang Y and Martin RC:
Epithelial cell adhesion molecule in human hepatocellular carcinoma
cell lines: A target of chemoresistence. BMC Cancer. 16:2282016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng J, Zhao L, Wang Y, Zhao S and Cui M:
Clinicopathology of EpCAM and EGFR in human epithelial ovarian
carcinoma. Open Med (Wars). 12:39–44. 2017.PubMed/NCBI
|
|
24
|
Tayama S, Motohara T, Narantuya D, Li C,
Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano O and Katabuchi
H: The impact of EpCAM expression on response to chemotherapy and
clinical outcomes in patients with epithelial ovarian cancer.
Oncotarget. 8:44312–44325. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bokemeyer C: Catumaxomab-trifunctional
anti-EpCAM antibody used to treat malignant ascites. Expert Opin
Biol Ther. 10:1259–1269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
https://www.ema.europa.eu/documents/public-statement/publicstatement-removab-withdrawal-marketing-authorisation-european-union_en.pdf20–11.
2018
|
|
27
|
Zheng X, Fan X, Fu B, Zheng M, Zhang A,
Zhong K, Yan J, Sun R, Tian Z and Wei H: EpCAM inhibition
sensitizes chemoresistant leukemia to immune surveillance. Cancer
Res. 77:482–493. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Guo XQ, Niu XL, Wu J, Zhu YQ and
Mao LQ: Relationship of IL-6 and IL-8 secretion in epithelial
ovarian cancer cell lines with their sensitivity to tamoxifen as
well as MAPK, Akt and estrogen receptor phosphorylation. Xi Bao Yu
Fen Zi Mian Yi Xue Za Zhi. 26:21–24. 2010.(In Chinese). PubMed/NCBI
|
|
29
|
Asschert JG, Vellenga E, Ruiters MH and de
Vries EG: Regulation of spontaneous and TNF/INF-induced IL-6
expression in two human ovarian-carcinoma cell lines. Int J Cancer.
82:244–249. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li FF, Shen J, Shen HJ, Zhang X, Cao R,
Zhang Y, Qui Q, Lin XX, Xie YC, Zhang LH, et al: Shp2 plays an
important role in acute cigarette smoke-mediated lung inflammation.
J Immunol. 189:3159–3167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ke Y, Zhang EE, Hagihara K, Wu D, Pang Y,
Klein R, Curran T, Ranscht B and Feng GS: Deletion of Shp2 in the
brain leads to defective proliferation and differentiation in
neural stem cells and early postnatal lethality. Mol Cell Biol.
27:6706–6717. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lehmann U, Schmitz J, Weissenbach M,
Sobota RM, Hortner M, Friederichs K, Behrmann I, Tsiaris W, Sasaki
A, Schneider-Mergener J, et al: SHP2 and SOCS3 contribute to
Tyr-759-dependent attenuation of interleukin-6 signaling through
gp130. J Biol Chem. 278:661–671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fischer P, Lehmann U, Sobota RM, Schmitz
J, Niemand C, Linnemann S, Haan S, Behrmann I, Yoshimura A,
Johnston JA, et al: The role of the inhibitors of interleukin-6
signal transduction SHP2 and SOCS3 for desensitization of
interleukin-6 signaling. Biochem J. 378:449–460. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mamik MK and Ghorpade A: Src homology-2
domain-containing protein tyrosine phosphatase (SHP) 2 and p38
regulate the expression of chemokine CXCL8 in human astrocytes.
PLoS One. 7:e455962012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schafer ZT and Brugge JS: IL-6 involvement
in epithelial cancers. J Clin Invest. 117:3660–3663. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Feng GS: Shp-2 tyrosine phosphatase:
Signaling one cell or many. Exp Cell Res. 253:47–54. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
You M, Yu DH and Feng GS: Shp-2 tyrosine
phosphatase functions as a negative regulator of the
interferon-stimulated Jak/STAT pathway. Mol Cell Biol.
19:2416–2424. 1999. View Article : Google Scholar : PubMed/NCBI
|
